A VISIONaerie® approach
We discover, develop and commercialize first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases
News HighlightsAerie Pharmaceuticals Receives European Commission Approval for Roclanda® ... Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda® in the ... Aerie Pharmaceuticals Initiates Phase 2b Clinical Trial of AR-15512 (TRPM8 ...
Jan 15, 4:00 PM ET
52 - WEEK LOW/HIGH